Optimal management of allergic rhinitis

Area of Science:

• Pediatric Allergy and Immunology
• Respiratory Medicine
• Clinical Otolaryngology

Background:

• Allergic rhinitis (AR) is the most prevalent chronic childhood disease, frequently misdiagnosed or inadequately treated.
• Undertreated AR significantly diminishes quality of life, worsens asthma control, and is a key factor in asthma development.
• AR affects nasal passages and connected organs, presenting diverse symptoms requiring comprehensive management strategies.

Purpose of the Study:

• To review current evidence-based guidelines and management strategies for pediatric allergic rhinitis.
• To highlight the importance of accurate diagnosis, allergen avoidance, and appropriate pharmacotherapy.
• To discuss the role and emerging evidence for allergen-specific immunotherapy in children.

Main Methods:

• Review of recently published European Academy of Allergy and Clinical Immunology (EAACI) pediatric AR guidelines.
• Inclusion of patient care pathway information from the Royal College of Paediatrics and Child Health for AR and asthma.
• Analysis of pharmacotherapeutic options, including saline sprays, antihistamines, intranasal corticosteroids, and antileukotrienes.
• Evaluation of allergen-specific immunotherapy (subcutaneous and sublingual) efficacy and safety in pediatric populations.

Main Results:

• Evidence-based guidelines are crucial for improving AR disease control in children.
• Pharmacotherapy for AR ranges from saline sprays to intranasal corticosteroids and antihistamines, tailored to disease severity.
• Sublingual immunotherapy demonstrates efficacy and safety for grass pollen allergy in children; further research is needed for other allergens.
• Subcutaneous immunotherapy use in children is limited by safety and acceptability concerns regarding injections.

Conclusions:

• Comprehensive management of pediatric AR involves accurate diagnosis, allergen avoidance, and tailored pharmacotherapy.
• Allergen-specific immunotherapy offers a unique potential to modify long-term disease trajectory, with sublingual immunotherapy showing promise.
• Patient, caregiver, and practitioner education is essential for effective AR management and improved health outcomes.